RECRUITING

Bone Loss, Physical Function and Frailty in Older Women With Sickle Cell Trait Sickle Cell Trait

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a cross-sectional, clinical research study comparing postmenopausal women of African Descent (AD) with different hemoglobin genotypes: normal and sickle cell trait (SCT). This research study has two purposes. The first purpose is to determine whether having SCT is a risk factor for the development of bone thinning in older women. The second purpose is to investigate whether women with SCT have reduced muscle function and increased frailty compared to women without SCT. The investigators estimate enrolling 50 female volunteers who are at least 50 years old and have not had a menstrual period for at least 12 consecutive months. Volunteers need not know whether they have SCT as this will be evaluated as part of the study.

Official Title

Bone Loss, Physical Function and Frailty in Older Women With Sickle Cell Trait

Quick Facts

Study Start:2022-08-23
Study Completion:2025-08-23
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07083531

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:50 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Female of African Decent.
  2. * Age 50 years or older.
  3. * Lack of menstrual period for at least 12 consecutive months
  1. * Taking medications known to influence bone metabolism (e.g., glucocorticoids, hormonal therapy, cancer or chemotherapy meds, anti-resorptive medications or anabolic therapies).
  2. * Known metabolic bone disorder (e.g., uncontrolled thyroid disease, hyperparathyroidism, Vitamin D deficiency)
  3. * Taking an investigational drug
  4. * Documented sickle cell disease

Contacts and Locations

Study Contact

Zoe Green, BS
CONTACT
860.679.4656
zgreen@uchc.edu

Principal Investigator

Biree Andemariam, MD
PRINCIPAL_INVESTIGATOR
UConn Health

Study Locations (Sites)

UConn Health
Farmington, Connecticut, 06030
United States

Collaborators and Investigators

Sponsor: UConn Health

  • Biree Andemariam, MD, PRINCIPAL_INVESTIGATOR, UConn Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-08-23
Study Completion Date2025-08-23

Study Record Updates

Study Start Date2022-08-23
Study Completion Date2025-08-23

Terms related to this study

Keywords Provided by Researchers

  • Sickle Cell Disease (SCD)
  • Sickle Cell Trait (SCT)

Additional Relevant MeSH Terms

  • Sickle Cell Disease
  • Sickle Cell Trait